FDA DEVICE FACTS
DeepHealth ProstateAI
Quantib B.V.
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
DeepHealth ProstateAI is a Computer-Aided Detection and Diagnosis (CADe/x) software device developed to aid trained physicians in the detection and characterization of prostate cancer lesions using MR imaging data in patients aged 40 years and older. DeepHealth ProstateAI analyzes T2W, ADC and DWI MR images. Combined with the MR images the software requires a binary mask containing the prostate gland segmentation. Output consists of ROI candidates including segmentations, and per ROI a classification indicating the likelihood of prostate cancer. The device is intended to assist in the detection of prostate cancer across the full range of grade groups (ISUP Grade Group ≥ 1), including clinically significant prostate cancer (ISUP Grade Group ≥ 2). Device outputs shall be input for a visualization and adaptation tool. DeepHealth ProstateAI is intended to be used as a concurrent reading aid for physicians assessing prostate MRI exams. Analysis by DeepHealth ProstateAI is not intended as a replacement for interpreting prostate abnormalities using MR image data consistent with clinical recommendations (e.g., including DCE information when available); nor should patient management decisions be made solely based on the results of DeepHealth ProstateAI.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。